Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 4,191

The DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

Open access
Liu, Catherine, Bayer, Arnold, Cosgrove, Sara E., Daum, Robert S., Fridkin, Scott K., Gorwitz, Rachel J., Kaplan, Sheldon L., Karchmer, Adolf W., Levine, Donald P., Murray, Barbara E., Rybak, Michael J., Talan, David A., Chambers, Henry F.·2011·Clinical Infectious Diseases

Abstract

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciq146

Cites

317 of 317 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–317 of 317

Research works printed but not linked: 62

  1. Centers for Disease Control and Prevention, 2007, Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza–Louisiana Georgia, December 2006-January 2007, MMWR Morb Mortal Wkly Rep, 56, 325
  2. 1979, Canadian Task Force on the Periodic Health Examination, Can Med Assoc J, 121, 1193
  3. Nicholas, 1975, Concentration of clindamycin in human bone, Antimicrob Agents Chemother, 8, 220, 10.1128/AAC.8.2.220 · doi:10.1128/aac.8.2.220
  4. Joiner, 1981, Antibiotic levels in infected and sterile subcutaneous abscesses in mice, J Infect Dis, 143, 487, 10.1093/infdis/143.3.487 · doi:10.1093/infdis/143.3.487
  5. Panzer, 1972, Clindamycin levels in various body tissues and fluids, J Clin Pharmacol New Drugs, 12, 259, 10.1002/j.1552-4604.1972.tb00052.x · doi:10.1002/j.1552-4604.1972.tb00052.x
  6. Miller, 2010, Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases, Clin Infect Dis, 50, e63, 10.1086/652656 · doi:10.1086/652656
  7. Abdel-Rahman, 2008, Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections, Pediatr Infect Dis J, 27, 330, 10.1097/INF.0b013e318160edfc · doi:10.1097/inf.0b013e318160edfc
  8. Loeffler, 2002, Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients, Pediatr Infect Dis J, 21, 950, 10.1097/00006454-200210000-00013 · doi:10.1097/00006454-200210000-00013
  9. Norden, 1986, Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy, South Med J, 79, 947, 10.1097/00007611-198608000-00008 · doi:10.1097/00007611-198608000-00008
  10. Saravolatz, 2009, Telavancin: a novel lipoglycopeptide, Clin Infect Dis, 49, 1908, 10.1086/648438 · doi:10.1086/648438
  11. Sanchez, 1997, Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection, Enferm Infecc Microbiol Clin, 15, 10
  12. Cooper, 1986, Pharmacokinetics of vancomycin. Vancomycin: a comprehensive review of 30 years clinical experience, 23
  13. d'Oliveira, 2003, Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil, Microb Drug Resist, 9, 87, 10.1089/107662903764736382 · doi:10.1089/107662903764736382
  14. Libertin, 1983, Effects of trimethoprim-sulfamethoxazole and incubation atmosphere on isolation of group A streptococci, J Clin Microbiol, 18, 680, 10.1128/JCM.18.3.680-682.1983 · doi:10.1128/jcm.18.3.680-682.1983
  15. Trickett, 1973, Clinical experience: respiratory tract. Trimethoprim-sulfamethoxazole versus penicillin G in the treatment of group A beta-hemolytic streptococcal pharyngitis tonsillitis, J Infect Dis, 128, 693, 10.1093/infdis/128.Supplement_3.S693 · doi:10.1093/infdis/128.supplement_3.s693
  16. Tayal, 2006, The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department, Acad Emerg Med, 13, 384, 10.1197/j.aem.2005.11.074 · doi:10.1197/j.aem.2005.11.074
  17. Squire, 2005, ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections, Acad Emerg Med, 12, 601, 10.1197/j.aem.2005.01.016 · doi:10.1197/j.aem.2005.01.016
  18. Fleisher, 1980, Cellulitis: a prospective study, Ann Emerg Med, 9, 246, 10.1016/S0196-0644(80)80380-5 · doi:10.1016/s0196-0644(80)80380-5
  19. Fleisher, 1980, Cellulitis: bacterial etiology, clinical features, and laboratory findings, J Pediatr, 97, 591, 10.1016/S0022-3476(80)80014-X · doi:10.1016/s0022-3476(80)80014-x
  20. Newell, 1988, Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults, J Clin Microbiol, 26, 401, 10.1128/JCM.26.3.401-404.1988 · doi:10.1128/jcm.26.3.401-404.1988
  21. Centers for Disease Control Prevention, Environmental cleaning & disinfecting for MRSA: what's the difference between cleaners, sanitizers, and disinfectants? 2010
  22. American Academy of Pediatrics, Antibacterial Drugs for Newborn Infantsl
  23. Wendt, 2007, Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial, Infect Control Hosp Epidemiol, 28, 1036, 10.1086/519929 · doi:10.1086/519929
  24. Washington University School of Medicine, Staphylococcus aureus decolonization study (SuDS) (NCT00731783)
  25. Natividad Medical Center, A prospective trial of nasal mupirocin, hexachlorophene body Wash, systemic antibiotics for prevention of recurrent methicillin resistant staphylococcus aureus infections (NCT01049438)
  26. Los Angeles Biomedical Research Institute, A randomized clinical trial to prevent recurrent CA-MRSA infection (PRIMO) (NCT00560599)
  27. Chandorkar, 2009, Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years. [abstract number 1243]
  28. Boucher, 2006, Appropriateness of two-week therapy for catheter-related S. aureus bacteremia [abstract number L-1204]
  29. Conte, 2002, Intrapulmonary pharmacokinetics of linezolid, Antimicrob Agents Chemother, 46, 1475, 10.1128/AAC.46.5.1475-1480.2002 · doi:10.1128/aac.46.5.1475-1480.2002
  30. Daver, 2007, Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis, J Infect, 54, 539, 10.1016/j.jinf.2006.11.011 · doi:10.1016/j.jinf.2006.11.011
  31. Al-Nammari, 2007, Hematogenous methicillin-resistant Staphylococcus aureus spondylodiscitis, Spine (Phila Pa 1976), 32, 2480, 10.1097/BRS.0b013e318157393e · doi:10.1097/brs.0b013e318157393e
  32. Van der Auwera, 1985, Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections, Antimicrob Agents Chemother, 28, 467, 10.1128/AAC.28.4.467 · doi:10.1128/aac.28.4.467
  33. Priest, 2005, Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes, South Med J, 98, 854, 10.1097/01.smj.0000168666.98129.33 · doi:10.1097/01.smj.0000168666.98129.33
  34. Crompton, 2009, Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry, J Chemother, 21, 414, 10.1179/joc.2009.21.4.414 · doi:10.1179/joc.2009.21.4.414
  35. Shipton, 2007, Experience with daptomycin in Staphylococcus bone and joint infections: case series and emergence of nonsusceptibility, Infect Dis Clin Pract, 15, 324, 10.1097/IPC.0b013e318142cbbf · doi:10.1097/ipc.0b013e318142cbbf
  36. Chen, 2007, Experience with linezolid therapy in children with osteoarticular infections, Pediatr Infect Dis J, 26, 985, 10.1097/INF.0b013e31812e62dc · doi:10.1097/inf.0b013e31812e62dc
  37. Rao, 2007, Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series, Diagn Microbiol Infect Dis, 59, 173, 10.1016/j.diagmicrobio.2007.04.006 · doi:10.1016/j.diagmicrobio.2007.04.006
  38. Simpson, 2001, Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival, J Bone Joint Surg Br, 83, 403, 10.1302/0301-620X.83B3.0830403 · doi:10.1302/0301-620x.83b3.0830403
  39. Aboltins, 2007, Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid, Clin Microbiol Infect, 13, 586, 10.1111/j.1469-0691.2007.01691.x · doi:10.1111/j.1469-0691.2007.01691.x
  40. Zalavras, 2009, Infection following operative treatment of ankle fractures, Clin Orthop Relat Res, 467, 1715, 10.1007/s11999-009-0743-8 · doi:10.1007/s11999-009-0743-8
  41. Ballock, 2009, A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis, J Pediatr Orthop, 29, 636, 10.1097/BPO.0b013e3181b2b860 · doi:10.1097/bpo.0b013e3181b2b860
  42. Jorgenson, 2007, Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices, Pediatr Neurosurg, 43, 449, 10.1159/000108786 · doi:10.1159/000108786
  43. Myrianthefs, 2006, Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients, Antimicrob Agents Chemother, 50, 3971, 10.1128/AAC.00051-06 · doi:10.1128/aac.00051-06
  44. Beer, 2007, Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains, Antimicrob Agents Chemother, 51, 379, 10.1128/AAC.00515-06 · doi:10.1128/aac.00515-06
  45. Nagashima, 2008, Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report, J Infect Chemother, 14, 147, 10.1007/s10156-007-0582-Z · doi:10.1007/s10156-007-0582-z
  46. Ntziora, 2007, Linezolid for the treatment of patients with central nervous system infection, Ann Pharmacother, 41, 296, 10.1345/aph.1H307 · doi:10.1345/aph.1h307
  47. Vartzelis, 2005, Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant, Infection, 33, 36, 10.1007/s15010-005-4062-z · doi:10.1007/s15010-005-4062-z
  48. Schreffler, 2002, Treatment of cerebrospinal fluid shunt infections: a decision analysis, Pediatr Infect Dis J, 21, 632, 10.1097/00006454-200207000-00006 · doi:10.1097/00006454-200207000-00006
  49. Whitehead, 2001, The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons, Pediatr Neurosurg, 35, 205, 10.1159/000050422 · doi:10.1159/000050422
  50. Sacar, 2006, A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period, BMC Infect Dis, 6, 43, 10.1186/1471-2334-6-43 · doi:10.1186/1471-2334-6-43
  51. Elvy, 2008, Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin, J Antimicrob Chemother, 61, 461, 10.1093/jac/dkm501 · doi:10.1093/jac/dkm501
  52. Ho, 1986, In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus, Diagn Microbiol Infect Dis, 4, 133, 10.1016/0732-8893(86)90147-1 · doi:10.1016/0732-8893(86)90147-1
  53. Yanagisawa, 2007, Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin, J Infect Chemother, 13, 368, 10.1007/s10156-007-0551-6 · doi:10.1007/s10156-007-0551-6
  54. Ebert, 1987, In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and resistant S. aureus [abstract 439]
  55. Dudley, 1999, Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible intermediate S. aureus in the neutropenic murine thigh model [abstract 2031]
  56. Moise, 2000, Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus, Am J Health Syst Pharm, 57, S4, 10.1093/ajhp/57.suppl_2.S4 · doi:10.1093/ajhp/57.suppl_2.s4
  57. Lee-Such, 2006, Nephrotoxicity associated with aggressive vancomycin therapy [abstract #1298]
  58. Odio, 1984, Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children, J Pediatr, 105, 491, 10.1016/S0022-3476(84)80036-0 · doi:10.1016/s0022-3476(84)80036-0
  59. Kullar, 2009, High-dose daptomycin for complicated gram-positive infections [poster # 1984]
  60. Gebhart, 2007, Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid rifampin, Pharmacotherapy, 27, 476, 10.1592/phco.27.3.476 · doi:10.1592/phco.27.3.476
  61. Tan, 1993, Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia, Antimicrob Agents Chemother, 37, 2401, 10.1128/AAC.37.11.2401 · doi:10.1128/aac.37.11.2401
  62. Deville, 2003, Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates, Pediatr Infect Dis J, 22, S158, 10.1097/01.inf.0000086955.93702.c7 · doi:10.1097/01.inf.0000086955.93702.c7

Cited by

See all 4,191

Metadata

Authors
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., Rybak, M. J., Talan, D. A., & Chambers, H. F.
Venue
Clinical Infectious Diseases
Published
2011-02-01
Volume
52
Issue
3
Pages
e18-e55
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2108433768
Cited by
4,191
References
317
FWCI
199.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.